Analyst Price Targets — SNDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 27, 2026 5:03 pm | Stephen Willey | Stifel Nicolaus | $45.00 | $21.71 | StreetInsider | Syndax Pharmaceuticals (SNDX) PT Raised to $45 at Stifel |
| November 24, 2025 11:31 am | — | Barclays | $35.00 | $17.44 | TheFly | Syndax price target raised to $35 from $22 at Barclays |
| November 4, 2025 12:36 pm | — | UBS | $38.00 | $13.76 | TheFly | Syndax price target raised to $38 from $35 at UBS |
| November 4, 2025 10:09 am | Peter Lawson | Barclays | $22.00 | $13.76 | TheFly | Syndax price target raised to $22 from $19 at Barclays |
| September 10, 2025 9:10 am | — | Stifel Nicolaus | $44.00 | $15.73 | TheFly | Syndax resumed with a Buy at Stifel |
| July 15, 2025 10:51 am | David Dai | UBS | $35.00 | $9.80 | TheFly | Syndax price target lowered to $35 from $37 at UBS |
| July 10, 2025 8:56 am | Corinne Johnson | Goldman Sachs | $18.00 | $9.82 | TheFly | Syndax initiated with a Buy at Goldman Sachs |
| November 13, 2024 12:18 pm | George Farmer | Scotiabank | $18.00 | $20.04 | StreetInsider | Syndax Pharmaceuticals (SNDX) PT Lowered to $18 at Scotiabank |
| October 24, 2024 3:22 am | David Dai | UBS | $37.00 | $18.54 | StreetInsider | UBS Starts Syndax Pharmaceuticals (SNDX) at Buy |
| August 15, 2024 9:27 am | Yigal Nochomovitz | Citigroup | $34.00 | $20.09 | StreetInsider | Syndax Pharmaceuticals (SNDX) PT Raised to $34 at Citi |
Latest News for SNDX
SG Americas Securities LLC raised its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) by 184.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 129,227 shares of the company's stock after buying an additional 83,801 shares during the period. SG Americas Securities LLC
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the…
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have given a buy recommendation and one has given
DAFNA Capital Management sold 222,847 SNDX shares in the fourth quarter for an estimated roughly $4 million. Meanwhile, the quarter-end position value decreased by $1.87 million, reflecting both trading and price movements.
Kynam Capital reduced its Syndax Pharmaceuticals stake by 469,041 shares in the fourth quarter; the estimated trade size was $8.18 million based on average closing prices for the quarter. Meanwhile, the quarter-end position value increased by $38.07 million, reflecting both trading and share price changes.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SNDX.
U.S. House Trading
No House trades found for SNDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.